Stem definition | Drug id | CAS RN |
---|---|---|
muscarinic receptors antagonists | 2457 | 242478-37-1 |
Dose | Unit | Route |
---|---|---|
5 | mg | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 12.50 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.30 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 90 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 8.20 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 2.10 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.02 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 52 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Nov. 19, 2004 | FDA | ASTELLAS |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Dry mouth | 197.77 | 11.35 | 179 | 22505 | 55999 | 50526441 |
Multiple sclerosis relapse | 126.43 | 11.35 | 124 | 22560 | 42840 | 50539600 |
Urinary retention | 111.36 | 11.35 | 93 | 22591 | 26097 | 50556343 |
Fall | 105.96 | 11.35 | 360 | 22324 | 334572 | 50247868 |
Urinary incontinence | 71.25 | 11.35 | 75 | 22609 | 28133 | 50554307 |
Urinary tract infection | 67.35 | 11.35 | 237 | 22447 | 223783 | 50358657 |
Vision blurred | 64.88 | 11.35 | 122 | 22562 | 78525 | 50503915 |
Residual urine volume increased | 62.43 | 11.35 | 11 | 22673 | 20 | 50582420 |
Gait disturbance | 57.03 | 11.35 | 172 | 22512 | 149833 | 50432607 |
Multiple sclerosis | 52.66 | 11.35 | 55 | 22629 | 20438 | 50562002 |
Fear of eating | 49.44 | 11.35 | 14 | 22670 | 326 | 50582114 |
Dementia | 48.57 | 11.35 | 47 | 22637 | 15950 | 50566490 |
Maternal exposure during pregnancy | 48.44 | 11.35 | 7 | 22677 | 159771 | 50422669 |
Arteriovenous fistula occlusion | 47.94 | 11.35 | 14 | 22670 | 365 | 50582075 |
Blue toe syndrome | 46.99 | 11.35 | 14 | 22670 | 392 | 50582048 |
Constipation | 45.41 | 11.35 | 184 | 22500 | 185524 | 50396916 |
Drug intolerance | 40.52 | 11.35 | 24 | 22660 | 219080 | 50363360 |
Contraindicated product administered | 37.86 | 11.35 | 10 | 22674 | 148948 | 50433492 |
Hallucination | 36.75 | 11.35 | 71 | 22613 | 46586 | 50535854 |
Synovitis | 36.23 | 11.35 | 6 | 22678 | 123859 | 50458581 |
Lymphocyte count decreased | 35.51 | 11.35 | 51 | 22633 | 26256 | 50556184 |
Hand deformity | 33.84 | 11.35 | 3 | 22681 | 100196 | 50482244 |
Cerebellar syndrome | 33.51 | 11.35 | 20 | 22664 | 3291 | 50579149 |
Cutaneous T-cell dyscrasia | 30.89 | 11.35 | 7 | 22677 | 63 | 50582377 |
Cutaneous lupus erythematosus | 30.80 | 11.35 | 17 | 22667 | 2414 | 50580026 |
Infusion related reaction | 30.74 | 11.35 | 19 | 22665 | 169538 | 50412902 |
Renal pain | 30.40 | 11.35 | 23 | 22661 | 5596 | 50576844 |
Treatment failure | 30.10 | 11.35 | 12 | 22672 | 137625 | 50444815 |
Bladder sphincter atony | 29.55 | 11.35 | 8 | 22676 | 157 | 50582283 |
Balance disorder | 28.74 | 11.35 | 83 | 22601 | 70507 | 50511933 |
Dry throat | 28.33 | 11.35 | 22 | 22662 | 5562 | 50576878 |
Nodular rash | 27.83 | 11.35 | 8 | 22676 | 197 | 50582243 |
Confusional state | 27.17 | 11.35 | 159 | 22525 | 185769 | 50396671 |
Toxicity to various agents | 26.31 | 11.35 | 34 | 22650 | 212465 | 50369975 |
Discomfort | 26.19 | 11.35 | 8 | 22676 | 108372 | 50474068 |
Exposure during pregnancy | 25.74 | 11.35 | 11 | 22673 | 121004 | 50461436 |
Glossodynia | 25.39 | 11.35 | 10 | 22674 | 115559 | 50466881 |
Sinus arrest | 24.66 | 11.35 | 13 | 22671 | 1685 | 50580755 |
Bladder disorder | 24.49 | 11.35 | 23 | 22661 | 7520 | 50574920 |
Dysuria | 24.46 | 11.35 | 45 | 22639 | 28459 | 50553981 |
Disorientation | 24.36 | 11.35 | 51 | 22633 | 35433 | 50547007 |
Swelling | 23.99 | 11.35 | 33 | 22651 | 200839 | 50381601 |
Therapeutic product effect decreased | 23.62 | 11.35 | 16 | 22668 | 136034 | 50446406 |
Sinus node dysfunction | 23.21 | 11.35 | 17 | 22667 | 3938 | 50578502 |
Cystitis | 22.77 | 11.35 | 57 | 22627 | 44507 | 50537933 |
Poliomyelitis | 21.87 | 11.35 | 5 | 22679 | 47 | 50582393 |
Pyelonephritis | 21.62 | 11.35 | 30 | 22654 | 14959 | 50567481 |
Rheumatoid arthritis | 21.56 | 11.35 | 36 | 22648 | 202514 | 50379926 |
Dyskinesia | 21.45 | 11.35 | 42 | 22642 | 27819 | 50554621 |
Joint swelling | 21.43 | 11.35 | 49 | 22635 | 245237 | 50337203 |
Dyspepsia | 21 | 11.35 | 77 | 22607 | 74020 | 50508420 |
Renal function test abnormal | 20.80 | 11.35 | 14 | 22670 | 2835 | 50579605 |
Hallucination, visual | 20.72 | 11.35 | 31 | 22653 | 16551 | 50565889 |
Pericarditis | 20.53 | 11.35 | 5 | 22679 | 78684 | 50503756 |
Hypertonic bladder | 20.15 | 11.35 | 14 | 22670 | 2986 | 50579454 |
Muscular weakness | 19.98 | 11.35 | 90 | 22594 | 94923 | 50487517 |
Malaise | 19.10 | 11.35 | 232 | 22452 | 335300 | 50247140 |
Heat stroke | 18.88 | 11.35 | 8 | 22676 | 635 | 50581805 |
Micturition urgency | 17.44 | 11.35 | 20 | 22664 | 8244 | 50574196 |
Dizziness | 17.39 | 11.35 | 234 | 22450 | 346135 | 50236305 |
Hyponatraemia | 17.26 | 11.35 | 87 | 22597 | 96052 | 50486388 |
Lower urinary tract symptoms | 17.09 | 11.35 | 4 | 22680 | 42 | 50582398 |
Oscillopsia | 16.99 | 11.35 | 5 | 22679 | 134 | 50582306 |
Pain | 16.93 | 11.35 | 172 | 22512 | 578731 | 50003709 |
Colitis ischaemic | 16.80 | 11.35 | 21 | 22663 | 9462 | 50572978 |
Off label use | 16.40 | 11.35 | 301 | 22383 | 474125 | 50108315 |
Neurogenic bladder | 16.13 | 11.35 | 12 | 22672 | 2845 | 50579595 |
Torsade de pointes | 16.05 | 11.35 | 23 | 22661 | 11812 | 50570628 |
Thalamus haemorrhage | 15.97 | 11.35 | 7 | 22677 | 603 | 50581837 |
Hepatic enzyme increased | 15.96 | 11.35 | 23 | 22661 | 137357 | 50445083 |
Incontinence | 15.94 | 11.35 | 21 | 22663 | 9964 | 50572476 |
Upper gastrointestinal haemorrhage | 15.93 | 11.35 | 27 | 22657 | 16008 | 50566432 |
Lower respiratory tract infection | 15.47 | 11.35 | 12 | 22672 | 95189 | 50487251 |
Dry eye | 15.30 | 11.35 | 40 | 22644 | 32055 | 50550385 |
Drug abuse | 15.23 | 11.35 | 4 | 22680 | 59842 | 50522598 |
Wound | 15.18 | 11.35 | 15 | 22669 | 105779 | 50476661 |
Labelled drug-drug interaction medication error | 15.16 | 11.35 | 21 | 22663 | 10456 | 50571984 |
Benign renal neoplasm | 14.76 | 11.35 | 3 | 22681 | 15 | 50582425 |
Visual impairment | 14.59 | 11.35 | 65 | 22619 | 68210 | 50514230 |
Blood viscosity increased | 14.45 | 11.35 | 5 | 22679 | 228 | 50582212 |
Arthropathy | 14.22 | 11.35 | 31 | 22653 | 157875 | 50424565 |
Varicose ulceration | 13.81 | 11.35 | 6 | 22678 | 506 | 50581934 |
Vasculitic rash | 13.80 | 11.35 | 8 | 22676 | 1247 | 50581193 |
Pollakiuria | 13.78 | 11.35 | 32 | 22652 | 23819 | 50558621 |
Memory impairment | 13.67 | 11.35 | 71 | 22613 | 79289 | 50503151 |
Language disorder | 13.57 | 11.35 | 9 | 22675 | 1779 | 50580661 |
Atrial fibrillation | 13.56 | 11.35 | 85 | 22599 | 101660 | 50480780 |
Wrong technique in product usage process | 13.53 | 11.35 | 55 | 22629 | 55455 | 50526985 |
Cognitive disorder | 13.48 | 11.35 | 47 | 22637 | 44076 | 50538364 |
Abdominal discomfort | 13.31 | 11.35 | 56 | 22628 | 231585 | 50350855 |
Subacute hepatic failure | 13.10 | 11.35 | 4 | 22680 | 122 | 50582318 |
Poverty of speech | 12.89 | 11.35 | 5 | 22679 | 316 | 50582124 |
Cerebral haematoma | 12.81 | 11.35 | 11 | 22673 | 3200 | 50579240 |
Escherichia urinary tract infection | 12.37 | 11.35 | 19 | 22665 | 10376 | 50572064 |
Posture abnormal | 12.30 | 11.35 | 9 | 22675 | 2080 | 50580360 |
Hereditary angioedema with C1 esterase inhibitor deficiency | 12.23 | 11.35 | 3 | 22681 | 39 | 50582401 |
Inappropriate schedule of product administration | 12.19 | 11.35 | 64 | 22620 | 71767 | 50510673 |
Nodal rhythm | 12.07 | 11.35 | 8 | 22676 | 1579 | 50580861 |
JC polyomavirus test positive | 12.01 | 11.35 | 7 | 22677 | 1102 | 50581338 |
Hyperthermia | 12.00 | 11.35 | 16 | 22668 | 7680 | 50574760 |
Lip swelling | 11.97 | 11.35 | 31 | 22653 | 24705 | 50557735 |
Delirium | 11.94 | 11.35 | 41 | 22643 | 38151 | 50544289 |
Urge incontinence | 11.92 | 11.35 | 6 | 22678 | 707 | 50581733 |
Acute kidney injury | 11.80 | 11.35 | 155 | 22529 | 227903 | 50354537 |
Febrile neutropenia | 11.69 | 11.35 | 16 | 22668 | 97651 | 50484789 |
Airway remodelling | 11.48 | 11.35 | 3 | 22681 | 51 | 50582389 |
Muscle strain | 11.46 | 11.35 | 15 | 22669 | 7073 | 50575367 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Dry mouth | 94.18 | 15.01 | 69 | 9731 | 21715 | 29543012 |
Urinary retention | 90.71 | 15.01 | 79 | 9721 | 31819 | 29532908 |
Confusional state | 78.79 | 15.01 | 147 | 9653 | 127730 | 29436997 |
Hallucination | 63.27 | 15.01 | 76 | 9724 | 44636 | 29520091 |
Constipation | 56.71 | 15.01 | 120 | 9680 | 114040 | 29450687 |
Fall | 52.71 | 15.01 | 153 | 9647 | 177025 | 29387702 |
Urinary incontinence | 31.86 | 15.01 | 33 | 9767 | 16448 | 29548279 |
Duplicate therapy error | 29.41 | 15.01 | 7 | 9793 | 110 | 29564617 |
Urosepsis | 29.28 | 15.01 | 26 | 9774 | 10720 | 29554007 |
Urinary tract infection | 29.09 | 15.01 | 70 | 9730 | 72284 | 29492443 |
Gastrointestinal hypomotility | 29.07 | 15.01 | 11 | 9789 | 882 | 29563845 |
Hallucination, visual | 28.91 | 15.01 | 30 | 9770 | 14985 | 29549742 |
Bladder cancer | 28.59 | 15.01 | 25 | 9775 | 10102 | 29554625 |
Epilepsy | 27.14 | 15.01 | 32 | 9768 | 18400 | 29546327 |
Hyponatraemia | 25.66 | 15.01 | 64 | 9736 | 67569 | 29497158 |
Delirium | 25.05 | 15.01 | 46 | 9754 | 39351 | 29525376 |
Dysuria | 23.65 | 15.01 | 33 | 9767 | 22407 | 29542320 |
Enterocolitis bacterial | 23.59 | 15.01 | 7 | 9793 | 264 | 29564463 |
Product name confusion | 21.75 | 15.01 | 5 | 9795 | 67 | 29564660 |
Hypertonic bladder | 20.80 | 15.01 | 10 | 9790 | 1446 | 29563281 |
Duodenitis haemorrhagic | 20.37 | 15.01 | 5 | 9795 | 90 | 29564637 |
Bladder discomfort | 19.60 | 15.01 | 5 | 9795 | 106 | 29564621 |
Pollakiuria | 19.52 | 15.01 | 26 | 9774 | 16890 | 29547837 |
Haematuria | 19.13 | 15.01 | 44 | 9756 | 44095 | 29520632 |
Somnolence | 18.75 | 15.01 | 71 | 9729 | 93884 | 29470843 |
Malaise | 18.67 | 15.01 | 103 | 9697 | 159499 | 29405228 |
Pneumonia aspiration | 18.62 | 15.01 | 39 | 9761 | 36698 | 29528029 |
Dementia | 18.43 | 15.01 | 21 | 9779 | 11637 | 29553090 |
Upper respiratory tract irritation | 18.38 | 15.01 | 4 | 9796 | 41 | 29564686 |
Cognitive disorder | 18.28 | 15.01 | 30 | 9770 | 23469 | 29541258 |
Body temperature decreased | 18.22 | 15.01 | 20 | 9780 | 10644 | 29554083 |
Blood pressure systolic increased | 18.09 | 15.01 | 25 | 9775 | 16820 | 29547907 |
Off label use | 18.06 | 15.01 | 165 | 9635 | 300635 | 29264092 |
Completed suicide | 17.89 | 15.01 | 4 | 9796 | 90242 | 29474485 |
Incontinence | 17.46 | 15.01 | 14 | 9786 | 5018 | 29559709 |
Micturition urgency | 17.12 | 15.01 | 14 | 9786 | 5159 | 29559568 |
Polyuria | 16.54 | 15.01 | 16 | 9784 | 7346 | 29557381 |
Lower urinary tract symptoms | 16.33 | 15.01 | 5 | 9795 | 210 | 29564517 |
Foetal heart rate disorder | 16.19 | 15.01 | 4 | 9796 | 74 | 29564653 |
On and off phenomenon | 15.45 | 15.01 | 9 | 9791 | 1919 | 29562808 |
Cataract | 15.33 | 15.01 | 27 | 9773 | 22351 | 29542376 |
Dizziness | 15.10 | 15.01 | 111 | 9689 | 189573 | 29375154 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Dry mouth | 154.12 | 11.35 | 155 | 26330 | 60263 | 64411984 |
Fall | 134.84 | 11.35 | 426 | 26059 | 416400 | 64055847 |
Urinary retention | 123.22 | 11.35 | 125 | 26360 | 49076 | 64423171 |
Multiple sclerosis relapse | 98.44 | 11.35 | 102 | 26383 | 41033 | 64431214 |
Confusional state | 79.74 | 11.35 | 262 | 26223 | 260882 | 64211365 |
Urinary tract infection | 71.26 | 11.35 | 233 | 26252 | 231363 | 64240884 |
Hallucination | 69.98 | 11.35 | 115 | 26370 | 72673 | 64399574 |
Urinary incontinence | 69.68 | 11.35 | 80 | 26405 | 36071 | 64436176 |
Constipation | 64.59 | 11.35 | 224 | 26261 | 229113 | 64243134 |
Fear of eating | 61.42 | 11.35 | 17 | 26468 | 398 | 64471849 |
Multiple sclerosis | 58.46 | 11.35 | 54 | 26431 | 18887 | 64453360 |
Vision blurred | 53.48 | 11.35 | 116 | 26369 | 90200 | 64382047 |
Arteriovenous fistula occlusion | 52.43 | 11.35 | 16 | 26469 | 533 | 64471714 |
Residual urine volume increased | 52.00 | 11.35 | 9 | 26476 | 16 | 64472231 |
Gait disturbance | 46.57 | 11.35 | 166 | 26319 | 171989 | 64300258 |
Toxicity to various agents | 45.88 | 11.35 | 49 | 26436 | 363464 | 64108783 |
Blue toe syndrome | 43.32 | 11.35 | 14 | 26471 | 564 | 64471683 |
Malaise | 41.20 | 11.35 | 291 | 26194 | 395956 | 64076291 |
Hyponatraemia | 40.94 | 11.35 | 144 | 26341 | 148195 | 64324052 |
Drug abuse | 39.97 | 11.35 | 4 | 26481 | 132370 | 64339877 |
Hallucination, visual | 38.24 | 11.35 | 52 | 26433 | 27782 | 64444465 |
Dysuria | 35.84 | 11.35 | 63 | 26422 | 41994 | 64430253 |
Renal pain | 34.23 | 11.35 | 26 | 26459 | 6948 | 64465299 |
Disorientation | 32.23 | 11.35 | 71 | 26414 | 55757 | 64416490 |
Cutaneous T-cell dyscrasia | 31.50 | 11.35 | 7 | 26478 | 63 | 64472184 |
Cutaneous lupus erythematosus | 30.63 | 11.35 | 17 | 26468 | 2665 | 64469582 |
Dyskinesia | 29.75 | 11.35 | 56 | 26429 | 39332 | 64432915 |
Hypertonic bladder | 29.33 | 11.35 | 18 | 26467 | 3400 | 64468847 |
Dizziness | 29.17 | 11.35 | 287 | 26198 | 429876 | 64042371 |
Dementia | 28.84 | 11.35 | 39 | 26446 | 20727 | 64451520 |
Lower urinary tract symptoms | 28.64 | 11.35 | 8 | 26477 | 194 | 64472053 |
Balance disorder | 28.08 | 11.35 | 87 | 26398 | 83839 | 64388408 |
Cerebellar syndrome | 27.53 | 11.35 | 20 | 26465 | 4996 | 64467251 |
Delirium | 27.23 | 11.35 | 76 | 26409 | 69118 | 64403129 |
Incontinence | 27.18 | 11.35 | 29 | 26456 | 12052 | 64460195 |
Infusion related reaction | 25.78 | 11.35 | 18 | 26467 | 164449 | 64307798 |
Gastrointestinal hypomotility | 25.48 | 11.35 | 13 | 26472 | 1720 | 64470527 |
Cystitis | 25.46 | 11.35 | 55 | 26430 | 42620 | 64429627 |
Nodular rash | 25.00 | 11.35 | 8 | 26477 | 312 | 64471935 |
Bladder cancer | 24.08 | 11.35 | 26 | 26459 | 10948 | 64461299 |
Treatment failure | 23.94 | 11.35 | 9 | 26476 | 116807 | 64355440 |
Duplicate therapy error | 23.93 | 11.35 | 7 | 26478 | 201 | 64472046 |
Pollakiuria | 22.79 | 11.35 | 44 | 26441 | 31486 | 64440761 |
Poliomyelitis | 22.21 | 11.35 | 5 | 26480 | 48 | 64472199 |
Sinus node dysfunction | 22.11 | 11.35 | 20 | 26465 | 6808 | 64465439 |
Systemic lupus erythematosus | 21.80 | 11.35 | 3 | 26482 | 77609 | 64394638 |
Micturition urgency | 21.79 | 11.35 | 24 | 26461 | 10335 | 64461912 |
Synovitis | 21.39 | 11.35 | 7 | 26478 | 99083 | 64373164 |
Urosepsis | 21.34 | 11.35 | 35 | 26450 | 22059 | 64450188 |
Dyspepsia | 21.31 | 11.35 | 77 | 26408 | 80235 | 64392012 |
Bladder discomfort | 21.26 | 11.35 | 8 | 26477 | 508 | 64471739 |
Neurogenic bladder | 21.17 | 11.35 | 15 | 26470 | 3604 | 64468643 |
Sinus arrest | 20.89 | 11.35 | 14 | 26471 | 3076 | 64469171 |
Maternal exposure during pregnancy | 20.30 | 11.35 | 7 | 26478 | 95877 | 64376370 |
Renal function test abnormal | 19.91 | 11.35 | 15 | 26470 | 3959 | 64468288 |
Epilepsy | 19.75 | 11.35 | 43 | 26442 | 33488 | 64438759 |
Upper respiratory tract irritation | 18.91 | 11.35 | 5 | 26480 | 98 | 64472149 |
Completed suicide | 18.82 | 11.35 | 40 | 26445 | 224374 | 64247873 |
Liver function test abnormal | 18.42 | 11.35 | 60 | 26425 | 59341 | 64412906 |
Cognitive disorder | 18.32 | 11.35 | 57 | 26428 | 55030 | 64417217 |
Freezing phenomenon | 18.21 | 11.35 | 10 | 26475 | 1536 | 64470711 |
Enterocolitis bacterial | 17.99 | 11.35 | 7 | 26478 | 487 | 64471760 |
Dry throat | 17.75 | 11.35 | 17 | 26468 | 6215 | 64466032 |
Memory impairment | 17.75 | 11.35 | 76 | 26409 | 85606 | 64386641 |
Duodenitis haemorrhagic | 17.64 | 11.35 | 5 | 26480 | 128 | 64472119 |
Muscular weakness | 17.17 | 11.35 | 100 | 26385 | 127238 | 64345009 |
Product name confusion | 16.61 | 11.35 | 5 | 26480 | 159 | 64472088 |
Hand deformity | 16.33 | 11.35 | 3 | 26482 | 62768 | 64409479 |
Lymphocyte count decreased | 16.30 | 11.35 | 45 | 26440 | 40654 | 64431593 |
Pyelonephritis | 16.20 | 11.35 | 27 | 26458 | 17239 | 64455008 |
Haematuria | 16.06 | 11.35 | 58 | 26427 | 60413 | 64411834 |
On and off phenomenon | 16.04 | 11.35 | 11 | 26474 | 2508 | 64469739 |
Oscillopsia | 16.04 | 11.35 | 5 | 26480 | 179 | 64472068 |
Cystitis interstitial | 15.23 | 11.35 | 8 | 26477 | 1124 | 64471123 |
Therapeutic product effect decreased | 15.14 | 11.35 | 15 | 26470 | 115336 | 64356911 |
Thalamus haemorrhage | 15.12 | 11.35 | 9 | 26476 | 1610 | 64470637 |
Neutropenia | 14.59 | 11.35 | 50 | 26435 | 239574 | 64232673 |
Somnolence | 14.31 | 11.35 | 137 | 26348 | 203508 | 64268739 |
Benign renal neoplasm | 14.17 | 11.35 | 3 | 26482 | 21 | 64472226 |
Blood viscosity increased | 13.89 | 11.35 | 5 | 26480 | 280 | 64471967 |
Pain | 13.84 | 11.35 | 153 | 26332 | 553358 | 63918889 |
Labelled drug-drug interaction medication error | 13.81 | 11.35 | 29 | 26456 | 22033 | 64450214 |
Acute disseminated encephalomyelitis | 13.64 | 11.35 | 5 | 26480 | 295 | 64471952 |
Rheumatoid arthritis | 13.18 | 11.35 | 30 | 26455 | 164264 | 64307983 |
Loss of consciousness | 13.12 | 11.35 | 105 | 26380 | 148260 | 64323987 |
Oral mucosal eruption | 13.04 | 11.35 | 6 | 26479 | 633 | 64471614 |
Bladder disorder | 13.00 | 11.35 | 16 | 26469 | 7751 | 64464496 |
Arthralgia | 12.81 | 11.35 | 118 | 26367 | 442142 | 64030105 |
Mucosal inflammation | 12.52 | 11.35 | 5 | 26480 | 62579 | 64409668 |
Pericarditis | 12.50 | 11.35 | 5 | 26480 | 62511 | 64409736 |
Atrial fibrillation | 12.47 | 11.35 | 116 | 26369 | 170973 | 64301274 |
Electrocardiogram QT prolonged | 12.45 | 11.35 | 65 | 26420 | 79383 | 64392864 |
Stoma site pain | 12.44 | 11.35 | 7 | 26478 | 1126 | 64471121 |
Hereditary angioedema with C1 esterase inhibitor deficiency | 12.42 | 11.35 | 3 | 26482 | 40 | 64472207 |
Drug hypersensitivity | 12.30 | 11.35 | 53 | 26432 | 237762 | 64234485 |
Drug intolerance | 12.29 | 11.35 | 38 | 26447 | 187954 | 64284293 |
Lactic acidosis | 12.13 | 11.35 | 5 | 26480 | 61405 | 64410842 |
Acute kidney injury | 12.13 | 11.35 | 255 | 26230 | 448985 | 64023262 |
Tenoplasty | 12.10 | 11.35 | 3 | 26482 | 45 | 64472202 |
Cerebral ventricular rupture | 12.01 | 11.35 | 5 | 26480 | 415 | 64471832 |
Genital pain | 11.85 | 11.35 | 5 | 26480 | 429 | 64471818 |
Secondary progressive multiple sclerosis | 11.84 | 11.35 | 7 | 26478 | 1236 | 64471011 |
Escherichia urinary tract infection | 11.53 | 11.35 | 19 | 26466 | 12018 | 64460229 |
Pseudomembranous colitis | 11.41 | 11.35 | 12 | 26473 | 4904 | 64467343 |
None
Source | Code | Description |
---|---|---|
ATC | G04BD08 | GENITO URINARY SYSTEM AND SEX HORMONES UROLOGICALS UROLOGICALS Drugs for urinary frequency and incontinence |
ATC | G04CA53 | GENITO URINARY SYSTEM AND SEX HORMONES UROLOGICALS DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY Alpha-adrenoreceptor antagonists |
FDA MoA | N0000000125 | Cholinergic Muscarinic Antagonists |
MeSH PA | D018678 | Cholinergic Agents |
MeSH PA | D018680 | Cholinergic Antagonists |
MeSH PA | D018727 | Muscarinic Antagonists |
MeSH PA | D018377 | Neurotransmitter Agents |
MeSH PA | D064804 | Urological Agents |
FDA EPC | N0000175700 | Cholinergic Muscarinic Antagonist |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Urgent desire to urinate | indication | 75088002 | |
Urge incontinence of urine | indication | 87557004 | |
Bladder muscle dysfunction - overactive | indication | 236633002 | |
Increased Urinary Frequency | indication | ||
Torsades de pointes | contraindication | 31722008 | |
Acute nephropathy | contraindication | 58574008 | |
Hepatic failure | contraindication | 59927004 | |
Prolonged QT interval | contraindication | 111975006 | |
Gastrointestinal obstruction | contraindication | 126765001 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Bladder outflow obstruction | contraindication | 236645006 | |
Retention of urine | contraindication | 267064002 | |
Gastric retention | contraindication | 307227006 | |
Angle-closure glaucoma | contraindication | 392291006 | DOID:13550 |
Gastrointestinal hypomotility | contraindication | 421807004 | |
Congenital long QT syndrome | contraindication | 442917000 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 8.21 | Basic |
None
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
1MG/ML | VESICARE LS | ASTELLAS | N209529 | May 26, 2020 | RX | SUSPENSION | ORAL | May 26, 2023 | NEW PRODUCT |
1MG/ML | VESICARE LS | ASTELLAS | N209529 | May 26, 2020 | RX | SUSPENSION | ORAL | Nov. 26, 2023 | PEDIATRIC EXCLUSIVITY |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Muscarinic acetylcholine receptor M3 | GPCR | ANTAGONIST | IC50 | 6.88 | CHEMBL | CHEMBL | |||
Muscarinic acetylcholine receptor M2 | GPCR | ANTAGONIST | IC50 | 6.24 | CHEMBL | CHEMBL | |||
Muscarinic acetylcholine receptor M5 | GPCR | ANTAGONIST | Ki | 7.20 | IUPHAR | ||||
Muscarinic acetylcholine receptor M1 | GPCR | IC50 | 7.20 | CHEMBL | |||||
Muscarinic acetylcholine receptor M4 | GPCR | ANTAGONIST | Ki | 6.80 | IUPHAR | ||||
Muscarinic acetylcholine receptor M2 | GPCR | Ki | 6.92 | CHEMBL | |||||
Muscarinic acetylcholine receptor M1 | GPCR | Ki | 8 | CHEMBL | |||||
Muscarinic acetylcholine receptor M3 | GPCR | Ki | 8 | CHEMBL |
ID | Source |
---|---|
4024390 | VUID |
N0000022393 | NUI |
D01269 | KEGG_DRUG |
242478-38-2 | SECONDARY_CAS_RN |
4021510 | VANDF |
4024390 | VANDF |
C1099677 | UMLSCUI |
CHEBI:135530 | CHEBI |
CHEMBL1734 | ChEMBL_ID |
CHEMBL1200803 | ChEMBL_ID |
DB01591 | DRUGBANK_ID |
D000069464 | MESH_DESCRIPTOR_UI |
154059 | PUBCHEM_CID |
7483 | IUPHAR_LIGAND_ID |
8155 | INN_ID |
A8910SQJ1U | UNII |
322167 | RXNORM |
19082 | MMSL |
256920 | MMSL |
63797 | MMSL |
d05413 | MMSL |
008712 | NDDF |
008713 | NDDF |
407030007 | SNOMEDCT_US |
407031006 | SNOMEDCT_US |
426324001 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Solifenacin succinate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-3795 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 26 sections |
Solifenacin succinate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-3795 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 26 sections |
Solifenacin succinate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-3796 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 26 sections |
Solifenacin succinate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-3796 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 26 sections |
solifenacin succinate | Human Prescription Drug Label | 1 | 27241-037 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 26 sections |
solifenacin succinate | Human Prescription Drug Label | 1 | 27241-038 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 26 sections |
Solifenacin Succinate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 29300-328 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 19 sections |
Solifenacin Succinate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 29300-329 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 19 sections |
Solifenacin Succinate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 35561-285 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 26 sections |
Solifenacin Succinate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 35561-286 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 26 sections |
Solifenacin Succinate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-739 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 18 sections |
Solifenacin Succinate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-740 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 18 sections |
Solifenacin Succinate | Human Prescription Drug Label | 1 | 46708-192 | TABLET, COATED | 5 mg | ORAL | ANDA | 27 sections |
Solifenacin Succinate | Human Prescription Drug Label | 1 | 46708-193 | TABLET, COATED | 10 mg | ORAL | ANDA | 27 sections |
SOLIFENACIN SUCCINATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50228-427 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 27 sections |
SOLIFENACIN SUCCINATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50228-428 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 27 sections |
VESIcare | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51248-150 | TABLET, FILM COATED | 5 mg | ORAL | NDA | 26 sections |
VESIcare | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51248-150 | TABLET, FILM COATED | 5 mg | ORAL | NDA | 26 sections |
VESIcare | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51248-151 | TABLET, FILM COATED | 10 mg | ORAL | NDA | 26 sections |
VESIcare | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51248-151 | TABLET, FILM COATED | 10 mg | ORAL | NDA | 26 sections |
VESIcareLS | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51248-250 | SUSPENSION | 1 mg | ORAL | NDA | 26 sections |
Solifenacin Succinate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-227 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 26 sections |
Solifenacin Succinate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-228 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 26 sections |
SOLIFENACIN SUCCINATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-254 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 27 sections |
SOLIFENACIN SUCCINATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-255 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 27 sections |
SOLIFENACIN SUCCINATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-471 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 27 sections |
SOLIFENACIN SUCCINATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-472 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 27 sections |
VESIcare | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-4705 | TABLET, FILM COATED | 10 mg | ORAL | NDA | 26 sections |
VESIcare | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-5398 | TABLET, FILM COATED | 5 mg | ORAL | NDA | 26 sections |
Solifenacin Succinate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60505-4702 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 26 sections |